SKINBIO THERAP LS-01 risk profile
33 Normal where most of the sector sits
Measured 21 October 2026 from 5KW's filed statements. Recomputed nightly.
33 (Normal), driven by Cash conversion at 100, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 93 | Acute | Stable | Drawdown from the 52-week high — 77.2% |
| Operating pressure | 0 | Contained | Stable | Costs outgrowing revenue — -245.5 percentage points |
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -0.13x |
| Leverage and coverage | 35 | Normal | Easing | Interest cover — -2.14x |
| Competitive position | 20 | Normal | Stable | R&D-intensity gap against peers — -78.8 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for SKINBIO THERAP LS-01